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To the Editor
Last year, it was stated in this journal that Non-
Alcoholic Fatty Liver Disease (NAFLD) is becoming 
the biggest cause of liver disease in western countries 
(1). NAFLD may gain importance as Non-Alcoholic 
Steatohepatitis (NASH), a specific and serious form of 
NAFLD, is on the rise. It is estimated that in Belgium 
3-4% of the population are affected by NASH, and it is 
projected that the prevalence will double by 2030 (2). 
Currently, over 90 drugs are being developed to treat 
NASH.
NASH is associated with a 30% or more loss in quality 
of life of the patient and may lead to death. Current 
treatments for NASH are based on lifestyle interventions 
(i.e. diet, physical activity) (1).  Unfortunately, it has 
been estimated that less than 10% of the patients manage 
to maintain these changes in order for the hepatic 
fibrosis to regress. Due to the global obesity epidemic 
and complications of NASH, economic analyses indicate 
growing costs for the healthcare system and society 
overall. For instance, liver cirrhosis is associated with 
a 19% absenteeism rate and a 45% presenteeism rate. 
A rough estimate for NASH in Belgium shows direct 
annual medical cost to range between 100 to 400 million 
euro (3). 
How will our welfare system cope with welfare 
diseases such as NASH given its rising cost? The 
impact lifestyle choices have on health raises major 
questions for patients, healthcare professionals and 
policy makers. Policy makers are grappling with the 
concept of individual responsibility and health risks even 
in a solidarity-based system like Belgium’s. Recently, 
societal debate was spurred when non-smoking was an 
eligibility criterium to be granted access to a drug to treat 
lung fibrosis. Does the right to health care also imply the 
personal responsibility to live healthy? Or is freedom 
to choose a healthy lifestyle inherently limited, as it 
is largely conditioned by the environment and genes? 
Regardless of the previous questions, does responsibility 
matter when we are confronted with human suffering and 
the resulting costs for society which could  be offset by 
new therapies?
Early prevention strategies remain most appropriate. 
Fundamentally, stimulating a healthy lifestyle would 
require a health system that facilitates the healthy life 
choices much more. This requires investments envisaging 
long term health and economic gains. This is however 
challenging given short legislatures at the policy level 
and financial incentives that pay per “medical treatment” 
(not prevention) at the level of health providers. 
Incentivising physicians and other caregivers to focus 
more on prevention is therefore recommended. But 
health promotion goes obviously beyond the healthcare 
sector. For example, investments in the education system 
and at the workplace, and collaborations with the food 
industry are needed to tackle overweight. Involving all 
stakeholders in the development of prevention strategies 
by using participatory design is therefore needed. 
Today, many policy actions can already help citizens 
to take control of their own health and way of life: 
investing in health literacy and self-development from 
primary education, integrating patient coaching modules 
into the training of caregivers; financially rewarding 
the amount of time caregivers take to educate their 
patients; developing detection programs; encouraging 
patients and providers to use cost-effective technologies; 
incentivizing patients to go for yearly general check-
ups; and finally investing in better data collection about 
the disease and policy measures. Finally, we hope that 
policy makers, health care professionals and patients will 
start to discuss how we can prevent the looming dangers 
of welfare diseases, while safeguarding our values of 
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